Trasylol is a drug manufactured by the German Pharmaceutical company Bayer. It was typically used during heart bypass surgey to prevent bleeding. Recently, two studies were released that linked Trasylol to higher risks of death and kidney disease. Bayer AG, the maker of Trasylol, claims those studies are flawed.
The two studies were released on Feb. 21 in the New England Journal of Medicine. As I noted in a previous entry, a study of 10,000 bypass patients at Duke University Medical Center found that 6.4 percent of the patients who were given Trasylol died within 30 days of surgery. That rate was nearly 2.5 times higher than patients who received a different drug or no anti-bleeding treatment.
The second study looked at 78,000 patients nationwide and found that the risk among patients given Trasylol was 64 percent higher than in those taking a different drug.
Bayer funded the second study — one of the two it now claims is flawed. But Public Citizen’s Health Research Group disagrees. An article in LawyersandSettlements.com notes that the consumer advocacy group believes the studies are convincing. The article also notes that the studies were rigorous enough for the editors of the New England Journal of Medicine.
The two latest studies are convincing. They are also consistent with the findings of Dr. Dennis Mangano of the Ischemia Research and Educational Foundation and a Canadian study that was halted because of deaths among Trasylol patients.
The lawyers of Carey, Danis & Lowe are experienced in helping people injured by a dangerous prescription drug. We will seek compensation for past and future medical expenses, past and future wages, pain and suffering, disability and other damages. We also represent family members in wrongful death cases.
We offer a free initial consultation for victims of dangerous medications. If you cannot make it to our office, we will come to you at the hospital or your home.
Contact the lawyers at Carey, Danis & Lowe today by calling 877-678-3400.